Adaptimmune hauls in $191M in an upsized immuno-oncology IPO

Wall Street

Adaptimmune Therapeutics ($ADAP), at work on cancer treatments that harness the body's natural defenses, pulled off a $191.3 million IPO, riding onto Wall Street amid investor exuberance for immuno-oncology.

The company, headquartered in Oxford, U.K., priced 11.25 million shares at $17 each, setting aside another roughly 1.7 million shares to cover overallotments and set its maximum deal value at nearly $220 million. With the proceeds, Adaptimmune plans to hit the gas on a stable of treatments based on T cell receptor, or TCR, technology, through which the biotech can sharpen the immune system's weaponry and train T cells to better cancers.

A cousin to high-profile CAR-T technology, TCR therapies are designed to train a patient's T cells to seek out specific antigens expressed by tumors liquid and solid. Adaptimmune's lead project, partnered with GlaxoSmithKline ($GSK), targets the NY-ESO antigen and is in the midst of clinical trials in 5 cancer varieties with more studies on the way, the company said. And the biotech has a wholly owned TCR aimed at the MAGE A-10 antigen now in preclinical development.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Adaptimmune's big Wall Street splash follows a now-well-trodden path for innovators in immuno-oncology. Juno Therapeutics ($JUNO), a leader in CAR-T, pulled of a $265 million IPO last year, just after competitors Bellicum Pharmaceuticals ($BLCM) and Kite Pharma ($KITE) raised about $140 million each in debuts of their own.

Each is reaping the benefits of widespread optimism that cancer immunotherapy can usher in a new era of efficacy in oncology, lining the pockets of innovators and their investors in the process. Newly launched immunotherapies from Merck ($MRK) and Bristol-Myers Squibb ($BMY) have thus far supported the idea, and many analysts believe cell treatments like CAR-Ts and TCRs could be the next big thing in a fast-growing market.


Special Report: FierceBiotech's 2014 Fierce 15 - Adaptimmune


Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.